Status:
COMPLETED
DNA Repair and Genetic Susceptibility to Lung Cancer
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Lung Cancer
Single Primary Lung Cancer
Eligibility:
All Genders
Brief Summary
The purpose of this study is to help us better understand the cellular changes that may lead to the development of lung cancer. We want to compare people with a second primary lung cancer with those w...
Eligibility Criteria
Inclusion
- Cases will be eligible for inclusion if:
- They have been diagnosed with a second primary lung cancer, and
- They speak English or a language for which we have a translated consent form, and
- They understand and agree to sign informed consent, and
- They agree to give us a blood sample, and
- They agree to give us a tissue sample when part of normal clinical procedures, and
- They agree to complete the study questionnaires, and
- They agree to have their pathology information reviewed. This could include biopsy specimens.
- Controls will be eligible for inclusion if
- They have been diagnosed with a first primary lung cancer, and
- They speak English or a language for which we have a translated consent form, and
- They understand and agree to sign informed consent, and
- They agree to give us a blood sample, and
- They agree to give us a tissue sample when part of normal clinical procedures, and
- They agree to complete the study questionnaires,
- They agree to have their pathology information reviewed. This will could include biopsy specimens.
Exclusion
- Subjects who do not meet the inclusion criteria as either cases or controls will not be eligible for this study.
- Control subjects who have a history of another cancer, other than nonmelanoma skin cancer or a first primary lung cancer, will not be eligible for this study.
- Control subjects who otherwise meet the eligibility requirements above but who have had chemotherapy and/or are currently being treated with chemotherapy will be excluded from the functional assay, but not from the genotyping.
Key Trial Info
Start Date :
February 11 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 24 2023
Estimated Enrollment :
218 Patients enrolled
Trial Details
Trial ID
NCT00611598
Start Date
February 11 2003
End Date
March 24 2023
Last Update
March 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065